+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Point-of-Care Glucose Testing Market by Product Type, End User, Distribution Channel, Test Type, Technology, Portability - Global Forecast to 2030- Product Image
Point-of-Care Glucose Testing Market by Product Type, End User, Distribution Channel, Test Type, Technology, Portability - Global Forecast to 2030- Product Image
Sale

Point-of-Care Glucose Testing Market by Product Type, End User, Distribution Channel, Test Type, Technology, Portability - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305543
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Point-of-Care Glucose Testing Market grew from USD 7.20 billion in 2024 to USD 7.77 billion in 2025. It is expected to continue growing at a CAGR of 7.57%, reaching USD 11.16 billion by 2030.

A Strategic Overview of Point-of-Care Glucose Testing

The landscape of point-of-care glucose testing has evolved into a critical junction between clinical precision and patient empowerment. As diabetes prevalence continues to climb globally, the need for rapid, accurate, and accessible glucose monitoring solutions has become imperative. This report delivers an incisive overview of the current state of the market, highlighting how technological breakthroughs and shifting healthcare paradigms have converged to redefine patient care at the point of need. It underscores the essential role of decentralized testing as healthcare systems strive to reduce burden on centralized labs while enhancing real-time decision-making.

Through detailed analysis, the introduction sets the stage by examining how patient expectations are reshaping device design, how regulatory bodies are aligning standards to foster innovation, and how digital integration is fast becoming the norm. By synthesizing these elements, readers will gain a clear understanding of the underlying forces shaping this dynamic market and the strategic implications for stakeholders across the value chain.

Transformative Shifts Redefining Glucose Testing at the Point of Care

Over the past few years, the market has witnessed fundamental shifts that transcend incremental improvements. Continuous glucose monitoring has moved beyond simple readings to deliver trend analysis, predictive alerts, and seamless data sharing with healthcare providers. The integration of software applications and cloud connectivity has transformed devices into comprehensive platforms, facilitating remote patient monitoring and enabling virtual care models. Regulatory authorities have responded with adaptive frameworks that accelerate approval pathways for non-invasive and innovative sensor technologies.

Furthermore, patient empowerment through self-management tools has become a key driver of market transformation. Populations are increasingly demanding devices that deliver clinical-grade accuracy without the inconvenience of frequent finger-sticks. In tandem, payers and healthcare institutions are incentivizing value-based care models, which prioritize outcomes and cost efficiency. These converging trends are not only reshaping product roadmaps but also redefining partnerships among technology developers, healthcare providers, and payers.

Assessing the Impact of 2025 Tariffs on US Glucose Testing

The introduction of new tariff measures in 2025 has imposed significant complexities on the supply chain for imported glucose testing components. Raw materials for sensors, test strips, and certain precision electronics have become subject to elevated duty rates, prompting many device manufacturers to reassess their sourcing strategies. These policy changes have accelerated initiatives to localize production, with several companies forging alliances with domestic foundries to mitigate cost pressures and avoid extended lead times.

At the same time, the ripple effects of these tariffs extend to pricing negotiations with distributors and end users. Hospitals and home care providers have begun scrutinizing total cost of ownership more closely, driving demand for integrated solutions that offset elevated per-unit costs through workflow efficiencies. In response, market participants are optimizing bundle offerings, enhancing software-driven analytics, and pursuing supply chain resilience to ensure uninterrupted delivery of critical testing supplies.

Deep Dive into Market Segmentation Drivers

A nuanced understanding of market dynamics requires dissecting each layer of segmentation. On the product side, continuous glucose monitoring devices have surged ahead of legacy meters as real-time and intermittently scanned systems deliver actionable insights that transcend static readings. Innovations in sensor technology, whether enzymatic or emerging optical approaches, are drawing attention for their potential to enhance accuracy and reduce calibration requirements. Software applications, paired with hardware, form an ecosystem that elevates patient engagement and supports remote monitoring.

Different end-user categories exhibit distinct adoption patterns. Hospitals and clinics, including large academic centers and smaller community facilities, prioritize integration with electronic health record systems and seamless clinical workflows. Diagnostic laboratories, both hospital based and independent, leverage high-throughput platforms to support clinical decision making across diverse patient populations. In the realm of home care, assisted programs coexist with direct-to-consumer self-monitoring models, reflecting an ongoing shift toward patient autonomy.

Distribution channels have also evolved to meet user needs. Direct sales approaches are complemented by hospital pharmacy networks, while the rise of online pharmacies-both manufacturer-operated portals and third-party marketplaces-has expanded accessibility. Retail pharmacies continue to serve as vital touchpoints for patient education and product replenishment. When considering test methodologies, invasive finger-stick testing remains prevalent, yet minimally invasive and non-invasive techniques are gaining traction among patients seeking gentler monitoring experiences. Underpinning these modalities, colorimetric, electrochemical, and photometric technologies each offer a unique balance of cost, accuracy, and ease of use. Finally, the dichotomy between benchtop and portable solutions underscores the balance between comprehensive laboratory capabilities and real-time patient mobility.

Regional Dynamics Shaping Global Market Trends

Regional markets reveal a tapestry of maturity and opportunity. In the Americas, established reimbursement frameworks and high rates of diabetes awareness support broad adoption of advanced monitoring devices. The United States leads with rapid incorporation of real-time continuous glucose monitoring, while Canada emphasizes integration with national telehealth programs. Meanwhile, Latin American markets are characterized by growing private-public partnerships aimed at expanding access and reducing cost barriers.

Across Europe, the Middle East, and Africa, regulatory harmonization through directives and regional bodies is facilitating cross-border device approvals. Western Europe emphasizes patient-centric care pathways and value-based procurement, whereas emerging markets in Eastern Europe and parts of the Middle East are investing in decentralized infrastructure to improve rural outreach. In Africa, pilot programs are testing non-invasive and low-cost platforms to address resource constraints and reach underserved populations.

The Asia-Pacific region presents a spectrum of adoption rates driven by demographic trends, healthcare spending, and local manufacturing capabilities. Developed markets such as Japan and Australia exhibit high per-capita usage of continuous monitoring, supported by robust reimbursement schemes. In contrast, rapidly expanding economies in South and Southeast Asia focus on scalable, cost-effective solutions. Government initiatives aimed at enhancing digital health frameworks further catalyze market growth and open avenues for public-private collaborations.

Competitive Landscape and Innovator Strategies

The competitive landscape is defined by a blend of established medical device conglomerates and nimble technology innovators. Veteran players continue to leverage their global distribution networks and comprehensive product portfolios, while specialized firms drive disruption through cutting-edge sensor research and digital platform integration. Partnerships between diagnostic leaders and software developers have given rise to end-to-end solutions that unify hardware performance with advanced data analytics.

Several companies have embarked on strategic acquisitions to bolster their technological moat, acquiring sensor specialists or software firms to enhance real-time analytics and predictive algorithms. Others are focusing on clinical collaborations to validate non-invasive testing approaches, aiming to accelerate regulatory approval and adoption. Collaboration with academic centers and clinical research organizations is also prevalent, ensuring that new devices meet stringent accuracy and safety benchmarks. As competitive pressures intensify, the ability to offer bundled solutions-combining monitoring hardware, software applications, and value-added services-has emerged as a critical differentiator.

Strategic Imperatives for Market Leadership

To secure a leadership position in this evolving market, industry players must prioritize cross-functional innovation and strategic agility. Investing in sensor technology research, particularly non-invasive and optical platforms, will address patient demand for less cumbersome monitoring. Concurrently, organizations should expand their digital ecosystems by developing intuitive software interfaces and robust data sharing capabilities that integrate seamlessly with electronic health records and telehealth platforms.

Building resilient supply chains is equally imperative in light of shifting trade policies. Companies should assess near-shoring opportunities and diversify sourcing partners to mitigate tariff-related costs and ensure uninterrupted product availability. Cultivating partnerships with payers and healthcare providers will enable the formulation of value-based contracting models that underscore improved patient outcomes and cost efficiencies. Finally, entering emerging markets through targeted pilot programs and local collaborations can foster brand presence and accelerate adoption among underserved populations.

Rigorous Methodology Underpinning the Research

This research is underpinned by a rigorous methodology that integrates primary and secondary data sources. Stakeholder interviews with clinicians, procurement officers, and patient advocacy groups provided real-world perspectives on evolving needs and adoption barriers. Insights gathered from device manufacturers and distribution partners offered clarity on supply chain dynamics and technological innovation trajectories.

Secondary research encompassed a comprehensive review of regulatory filings, clinical trial databases, industry publications, and patent literature to map competitive activities and emerging technologies. Data triangulation techniques ensured consistency and reliability, while segmentation frameworks were meticulously applied across product types, end users, distribution channels, test methodologies, technologies, and portability classifications. Regional analyses were grounded in an evaluation of healthcare infrastructure, reimbursement policies, and demographic trends to provide a holistic view of market dynamics.

Summative Insights and Future Directions

As the point-of-care glucose testing market continues to expand and diversify, the intersection of technology, policy, and patient demands will shape its trajectory. Continuous glucose monitoring, sensor innovations, digital integration, and strategic supply chain management stand out as pivotal elements in crafting sustainable growth. Regional nuances underscore the importance of tailored approaches that align with local healthcare ecosystems and regulatory environments.

Ultimately, organizations that embrace a holistic strategy-blending technological leadership with agile operational models and collaborative partnerships-will be best positioned to thrive. The insights presented in this summary offer a strategic compass for stakeholders seeking to navigate complex market forces and capitalize on emerging opportunities. By synthesizing these findings, decision-makers can chart a path toward enhanced patient outcomes, streamlined clinical workflows, and robust competitive advantage.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Continuous Glucose Monitoring Devices
      • Intermittently Scanned
      • Real Time
    • Glucose Meters
    • Sensors
      • Enzymatic
      • Optical
    • Software Apps
    • Test Strips
  • End User
    • Ambulatory Surgical Centers
    • Diagnostic Laboratories
      • Hospital Based Labs
      • Independent Labs
    • Home Care
      • Assisted Home Care
      • Self Monitoring
    • Hospitals & Clinics
      • Large Hospitals
      • Small Clinics
  • Distribution Channel
    • Direct Sales
    • Hospital Pharmacies
    • Online Pharmacies
      • Manufacturer Websites
      • Third Party Marketplaces
    • Retail Pharmacies
  • Test Type
    • Invasive
    • Minimally Invasive
    • Non Invasive
  • Technology
    • Colorimetric
    • Electrochemical
    • Photometric
  • Portability
    • Benchtop
    • Portable
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Dexcom, Inc.
  • Medtronic plc
  • Johnson & Johnson
  • Ascensia Diabetes Care Holdings AG
  • Nova Biomedical Corporation
  • Becton, Dickinson and Company
  • Sinocare Inc.
  • Nipro Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Point-of-Care Glucose Testing Market, by Product Type
8.1. Introduction
8.2. Continuous Glucose Monitoring Devices
8.2.1. Intermittently Scanned
8.2.2. Real Time
8.3. Glucose Meters
8.4. Sensors
8.4.1. Enzymatic
8.4.2. Optical
8.5. Software Apps
8.6. Test Strips
9. Point-of-Care Glucose Testing Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Diagnostic Laboratories
9.3.1. Hospital Based Labs
9.3.2. Independent Labs
9.4. Home Care
9.4.1. Assisted Home Care
9.4.2. Self Monitoring
9.5. Hospitals & Clinics
9.5.1. Large Hospitals
9.5.2. Small Clinics
10. Point-of-Care Glucose Testing Market, by Distribution Channel
10.1. Introduction
10.2. Direct Sales
10.3. Hospital Pharmacies
10.4. Online Pharmacies
10.4.1. Manufacturer Websites
10.4.2. Third Party Marketplaces
10.5. Retail Pharmacies
11. Point-of-Care Glucose Testing Market, by Test Type
11.1. Introduction
11.2. Invasive
11.3. Minimally Invasive
11.4. Non Invasive
12. Point-of-Care Glucose Testing Market, by Technology
12.1. Introduction
12.2. Colorimetric
12.3. Electrochemical
12.4. Photometric
13. Point-of-Care Glucose Testing Market, by Portability
13.1. Introduction
13.2. Benchtop
13.3. Portable
14. Americas Point-of-Care Glucose Testing Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Point-of-Care Glucose Testing Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Point-of-Care Glucose Testing Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Abbott Laboratories
17.3.2. F. Hoffmann-La Roche Ltd
17.3.3. Dexcom, Inc.
17.3.4. Medtronic plc
17.3.5. Johnson & Johnson
17.3.6. Ascensia Diabetes Care Holdings AG
17.3.7. Nova Biomedical Corporation
17.3.8. Becton, Dickinson and Company
17.3.9. Sinocare Inc.
17.3.10. Nipro Corporation
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. POINT-OF-CARE GLUCOSE TESTING MARKET MULTI-CURRENCY
FIGURE 2. POINT-OF-CARE GLUCOSE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. POINT-OF-CARE GLUCOSE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. POINT-OF-CARE GLUCOSE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. POINT-OF-CARE GLUCOSE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. POINT-OF-CARE GLUCOSE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INTERMITTENTLY SCANNED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY GLUCOSE METERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ENZYMATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY OPTICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SOFTWARE APPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST STRIPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL BASED LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INDEPENDENT LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ASSISTED HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SELF MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SMALL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY THIRD PARTY MARKETPLACES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY INVASIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PHOTOMETRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 79. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 80. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 82. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 83. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 84. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 86. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 87. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CANADA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 89. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 91. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 94. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 98. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 99. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 150. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 152. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 153. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 155. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 159. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 162. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 163. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 164. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 165. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 167. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 169. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 171. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 186. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 187. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 188. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 189. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 191. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 192. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 193. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 196. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 198. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 200. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 201. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 203. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 207. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 208. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. SPAIN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 210. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 222. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 224. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 234. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 246. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 248. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 251. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 255. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 270. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 272. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 273. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 275. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 276. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 277. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 279. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 280. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. QATAR POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 282. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 284. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 285. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 287. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 288. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHARMACIES, 2018-2030 (USD MILLION)
TABLE 291. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 292. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 293. FINLAND POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PORTABILITY, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING DEVICES, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY SENSORS, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN POINT-OF-CARE GLUCOSE TESTING MARKET SIZE, BY ONLINE PHAR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Point-of-Care Glucose Testing market report include:
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Dexcom, Inc.
  • Medtronic plc
  • Johnson & Johnson
  • Ascensia Diabetes Care Holdings AG
  • Nova Biomedical Corporation
  • Becton, Dickinson and Company
  • Sinocare Inc.
  • Nipro Corporation

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.16 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Network Point-of-Care Glucose Testing Market Size, Share & Trends Analysis Report By Product (i-STAT, Accu-Chek Inform II, StatStrip, HemoCue, CareSens Expert Plus), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Network Point-of-Care Glucose Testing Market Size, Share & Trends Analysis Report By Product (i-STAT, Accu-Chek Inform II, StatStrip, HemoCue, CareSens Expert Plus), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 90 Pages
  • Global
From
Point-of-Care Glucose Testing - Global Strategic Business Report - Product Image

Point-of-Care Glucose Testing - Global Strategic Business Report

  • Report
  • 72 Pages
  • Global
From
Point-of-Care Glucose Testing Market Report 2025 - Product Image

Point-of-Care Glucose Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Point of Care Glucose Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Point of Care Glucose Testing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Point of Care Glucose Testing Market 2024-2028 - Product Image

Point of Care Glucose Testing Market 2024-2028

  • Report
  • 134 Pages
  • Global
From

About the Point of Care Glucose Testing Market

Point of Care Glucose Testing (POCT) is a type of glucose testing that is performed outside of a laboratory setting. It is typically used to monitor glucose levels in patients with diabetes, and is often used in emergency situations. POCT is a convenient and cost-effective way to measure glucose levels, as it does not require a laboratory or specialized equipment. The results are usually available within minutes, allowing for quick and accurate diagnosis and treatment. POCT is also used to monitor glucose levels in pregnant women, as well as to diagnose and monitor other conditions such as hypoglycemia. The POCT market is growing rapidly, driven by the increasing prevalence of diabetes and other chronic conditions, as well as the need for rapid and accurate diagnosis and treatment. The market is also being driven by technological advancements, such as the development of portable and user-friendly devices. Some companies in the POCT market include Abbott, Roche, Siemens, and LifeScan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.